Effectiveness of statins in Medicare-eligible patients and patients > 65 years using clinical practice data

International Journal of Clinical Practice

Volumn 61, Issue 10, 2007, Pages 1634-1642

  Fox, K M ^a,e   Gandhi, S K ^b   Ohsfeldt, R L ^c   Blasetto, J W ^b   Davidson, M H ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d RADIANT RESEARCH   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GOAL ATTAINMENT; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIVARIATE ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 34548617373     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01538.x     Document Type: Article

References (25)

1. American Heart Association. Heart Disease and Stroke Statistics: 2006 Update. Dallas, TX : American Heart Association, 2006.
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
3. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 110 : 227 39.
4. Latts LM. Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans. Am J Med 2001 110 : 17S 23S.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000 160 : 459 67.
6. Rubins HB, Nelson DB, Noorbaloochi S et al. Effectiveness of lipid-lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs System. Am J Cardiol 2003 92 : 1177 82.
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998 339 : 1349 57.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 9.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002 360 : 7 22.
10. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004 364 : 685 96.
11. De Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004 292 : 1307 16.
12. Quilliam BJ, Perez HE, Andros V, Jones P. Quantifying the effect of applying the NCEP ATP III Criteria in a managed care population treated with statin therapy. J Manag Care Pharm 2004 10 : 244 50.
13. Harley CR, Williams SA, McDonough KL et al. Cholesterol management in a population of managed care enrollees. J Clin Outcome Manag 2003 10 : 147 54.
14. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996 100 : 605 10.
15. Straka RJ, Taheri R, Cooper SL et al. Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy 2001 21 : 818 27.
16. Bullano MF, Wertz DA, Yang GW et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006 26 : 469 78.
17. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999 341 : 498 511.
18. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003 92 : 152 60.
19. Fellstrom B, Zannad F, Schmieder R et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005 6 : 9 PM, on behalf of the JUPITER study group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003 108 : 2292 7.
20. Schuster H, Fox J. Investigating cardiovascular risk reduction - the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004 5 : 1187 200.
21. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 78.
22. Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002 113 : 625 9.
23. Koren MJ, Hunninghake DB, ALLIANCE investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The ALLIANCE study. J Am Coll Cardiol 2004 44 : 1772 9.
24. Bullano MF, Kamat S, Wertz DA et al. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm 2007 64 : 276 84.
25. Rubenstein S. Why generic doesn't always mean cheap. Wall St J 2007. http://online.WSJ.com/public/article (accessed April 14, 2007).